CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 410 enrolled
Drug / intervention
Everolimus +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00510068
NCT00510068Phase 3Completed
CompareCT.gov

A Randomized Double-blind Phase III Study of RAD001 10 mg/d Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Pancreatic Neuroendocrine Tumor (NET)

Novartis Pharmaceuticals·interventional·Posted Aug 1, 2007·Updated Jul 1, 2015

In Brief

A Phase 3 clinical trial evaluating Everolimus and Everolimus Placebo for Advanced Neuroendocrine Tumors of Pancreatic Origin. Completed, enrolled 410 participants across 82 sites in 18 countries.

Detailed Summary

The purpose of this study was to evaluate progression free survival in those participants assigned everolimus 10 mg/day plus Best Supportive Care versus those assigned to placebo plus Best Supportive Care in Advanced Neuroendocrine Tumors of pancreatic origin.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Neuroendocrine Tumors of Pancreatic Origin
CountriesBelgium, Brazil, Canada, France, Germany, Greece, Italy, Japan, Netherlands, Slovakia, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, United Kingdom, United States
Collaborators--

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 1, 2007
Enrollment StartJul 1, 2007
Primary CompletionFeb 1, 2010
Study CompletionMar 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 18.9 years ago

Interventions

Everolimusdrug

A 10-mg dose of everolimus was given by continuous oral daily dosing of two 5-mg tablets.

Everolimus Placebodrug

a 10-mg dose of matching placebo to Everolimus was given by continuous oral daily dosing of two 5-mg tablets.